Media & Press relations

Our latest press releases

November 05, 2025

Oxford Nanopore and bioMérieux launch AmPORE-TB, a Research Use Only sequencing-based solution to rapidly characterize drug resistant-tuberculosis

Oxford Nanopore Technologies and bioMérieux have announced the launch of AmPORE-TB, a Research Use Only (RUO) solution for the rapid characterization of mutations associated with antimicrobial resistance in Mycobacterium tuberculosis complex, using Oxford Nanopore sequencing technology.

Discover more

Swipe for more

November 04, 2025

Third-Quarter 2025 Business Review

bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the nine months ended September 30, 2025. Consolidated sales amounted to €2,992 million for the first nine months of 2025 versus €2,871 million for the prior-year period, representing a growth of +4.2% as reported.

Read more
October 06, 2025

bioMérieux and Henry Ford Health host U.S. thought leaders on antimicrobial resistance to accelerate diagnostics-driven stewardship and policy

bioMérieux and Henry Ford Health partnered to host a Summit focused on promoting practical actions to address the threat posed by antimicrobial resistance.

Read more
September 09, 2025

Altesa BioSciences and bioMérieux Announce Collaboration for Altesa’s Upcoming Phase 2B COPD Clinical Trial

Study will begin enrollment in Q1 2026 in the US and UK and leverage the BIOFIRE® SPOTFIRE® point-of-care diagnostics platform at U.S. sites.

Read more